CAMBRIDGE, Mass.,
June 20, 2017
/PRNewswire/ -- Akcea Therapeutics, Inc. today announced that
it has launched the proposed initial public offering of its common
stock.
Akcea is offering 9,620,000 shares of common stock and the
underwriters will have a 30-day option to purchase up to an
additional 1,443,000 shares of common stock. The initial public
offering price is currently expected to be between $12.00 and $14.00 per share. Akcea has
applied to list the shares on the NASDAQ Global Market under the
symbol "AKCA."
Cowen, Stifel and Wells Fargo Securities are acting as
joint book running managers for the offering. BMO Capital
Markets is acting as lead manager for the offering.
The proposed offering will be made only by means of a
prospectus. A copy of the preliminary prospectus may be obtained
from Cowen and Company, LLC, c/o Broadridge Financial Services,
1155 Long Island Avenue, Edgewood,
NY 11717, Attention: Prospectus Department, or by telephone
at (631) 274-2806; or from Stifel, Nicolaus & Company,
Incorporated, One Montgomery Street,
Suite 3700, San Francisco, CA
94104, or by telephone at (415) 364-2720, or by email at
syndprospectus@stifel.com; or from Wells Fargo Securities, LLC,
Attention: Equity Syndicate Department, 375 Park Avenue,
New York, NY 10152, or by
telephone at (800) 326-5897, or by email at
cmclientsupport@wellsfargo.com.
A registration statement relating to these securities has
been filed with the U.S. Securities and Exchange Commission but has
not yet become effective. These securities may not be sold, nor may
offers to buy be accepted, prior to the time the registration
statement becomes effective. This press release shall not
constitute an offer to sell or the solicitation of an offer to buy,
nor shall there be any sale of these securities in any state or
jurisdiction in which such offer, solicitation, or sale would be
unlawful prior to registration or qualification under the
securities laws of any such state or jurisdiction.
ABOUT AKCEA THERAPEUTICS
Akcea Therapeutics is a late-stage pharmaceutical company
focused on developing and commercializing drugs to treat patients
with serious cardiometabolic diseases caused by lipid disorders.
Akcea is advancing a mature pipeline of four novel drugs with the
potential to treat multiple diseases, including volanesorsen,
AKCEA-APO(a)-LRx, AKCEA-ANGPTL3-LRx and
AKCEA-APOCIII-LRx, which are all based on antisense
technology developed by Ionis Pharmaceuticals, Inc. The most
advanced drug in its pipeline, volanesorsen, has successfully
completed a Phase 3 clinical program for the treatment of familial
chylomicronemia syndrome, or FCS, and is currently in Phase 3
clinical development for the treatment of familial partial
lipodystrophy, or FPL. Akcea is assembling the infrastructure to
commercialize its drugs globally with a focus on lipid specialists
as the primary call point. Akcea is a subsidiary of Ionis
Pharmaceuticals, Inc. and is located in Cambridge, Massachusetts.
FORWARD-LOOKING STATEMENT
This press release includes forward-looking statements
regarding Akcea's financing plans, including statements related to
Akcea's offering of common stock. Any statement describing Akcea's
goals, expectations, financial or other projections, intentions or
beliefs is a forward-looking statement and should be considered an
at-risk statement. Such statements are subject to certain risks and
uncertainties, particularly those inherent in the process of
discovering, developing and commercializing drugs that are safe and
effective for use as human therapeutics, and in the endeavor of
building a business around such drugs. Akcea's forward-looking
statements also involve assumptions that, if they never materialize
or prove correct, could cause its results to differ materially from
those expressed or implied by such forward-looking statements.
Although Akcea's forward-looking statements reflect the good faith
judgment of its management, these statements are based only on
facts and factors currently known by Akcea. As a result, you are
cautioned not to rely on these forward-looking statements. These
and other risks concerning Akcea's programs are described in
additional detail in its registration statement on Form S-1, which
is on file with the SEC.
In this press release, unless the context requires
otherwise, "Ionis", "Akcea," "Company," "Companies" "we," "our,"
and "us" refers to Ionis Pharmaceuticals and/or Akcea
Therapeutics.
Akcea Therapeutics™ is a trademark of Ionis
Pharmaceuticals, Inc. Ionis Pharmaceuticals™ is a trademark of
Ionis Pharmaceuticals, Inc.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/akcea-therapeutics-launches-proposed-initial-public-offering-300476323.html
SOURCE Akcea Therapeutics